Generally, a cancer with a high tumor mutation burden (TMB) correlates with an increase in tumor-infiltrating lymphocytes (especially cytotoxic CD8+ T cells) and human leukocyte antigen (HLA) heterozygosity, which portend a good outcome in response to immunotherapy. The gene discussed is CD8A; the disease is neoplasm.